Heparansulphate: Effectiveness and tolerability in superficial thrombophlebitis. Controlled clinical study vs sulodexide;Efficacia e tollerabilita dell'eparansolfato nel trattamento della tromboflebite superficiale. Studio clinico controllato vs sulodexide

Minerva Cardioangiologica

Volumn 45, Issue 4, 1997, Pages 147-153

  Messa, G ^a   La Placa, G ^a   Puccetti, L ^a   Di Perri, T ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

heparansulphate; sulodexide; thrombophlebitis

Indexed keywords

ANTITHROMBIN III; HEPARAN SULFATE; SULODEXIDE; ANTILIPEMIC AGENT; GLYCOSAMINOGLYCAN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THROMBOPHLEBITIS; COMPARATIVE STUDY; MIDDLE AGED;

ADULT; AGED; ANTILIPEMIC AGENTS; FEMALE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; THROMBOPHLEBITIS;

EID: 0030612002     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Montorsi W, Annoni F. La semeiotica e la sintomatologia delle varici alla luce della fisiopatologia Minerva Angiol 1983,8:299-305.
2. Curri SB, Annoni F, Montorsi W. Les microvalvules dans la microcirculation. Phlebologie 1987;40:795-801.
3. Burnard KG, Clemenson G, Whimster J, Browse NL. Extravascular fibrin deposition in response to venous hypertension. Br J Surg 1976,63:660-7
4. Petruzzellis V, Florio T, Loconsole F, Troccoli T. Considerazioni patogenetiche sui manicotti perivasali di fibrina nelle ulcere flebopatiche. Minerva Angiol 1991,16.513-8.
5. Schafer A. Focusing of the clot: normal and pathologic mechanism. Ann Rev Med 1987;38:211-20.
6. Buonassisi V. Sulphated mucopolysaccharide synthesis and secretion in endothelial cell cultures. Exp Cell Res 1973;76:763-8.
7. Massaro TA, Glatz CE. Distribution of glycosaminoglycans in consecutive layers of the rabbit aorta. Artery 1979,5:1-13.
8. Tammi M, Seppala PO, Lehtonen A, Mottonen M Connective tissue components in normal and atherosclerotic human coronary arteries Atherosclerosis 1978;29:191-4.
9. Murata K, Yokoyama Y. Acid glucosaminoglycans in human coronary arteries, with special reference to the presence of heparin and related glucosaminoglycan. Experientia 1981,37:1139-41.
10. Buonassisi V, Colburn P Biological significance of heparansulphate proteoglycans. Ann NY Acad Sci 1982;401:76-84
11. Johnson EA. Characterization and separation of sulphated glycosaminoglycans. Pharmacol Res Commun 1982;14:289-320.
12. Gallagher JT, Lyon M, Steward WP. Structure and function of heparin sulphate proteoglycans. Biochem J 1986;236:313-25.
13. Segre G. Aspetti farmacologici dei glicosaminoglicani. Minerva Med 1986;77(40):1859-64.
14. Damus PS. Hics M, Rosenberg RD Anticoagulant action of heparin. Nature 1973;246:355-7.
15. Thomas DP, Merton RE, Barrowcliffe TW, Mulloy B, Johnson EA. Anti-factor Xa activity of heparan sulfate Thromb Res 1979;14(2-3):501-6.
16. Thomas DP, Johnson EA, Barrowcliffe TW The antithrombotic action of heparansulphate. In: Tesi M, Dormandy JA, editors. Vascular occlusion: epidemiological, pathophysiological and therapeutic aspects. London, New York: Academic Press 1981;37:377-82.
17. Papues EP, Stohr HA, Heimburger N. Study on the mechanism of heparin and related substances on the fibrinolytic system: Relationship between plasminogen activators and heparin. Thromb Res 1986;42:797-807.
18. Imamura T, Mitaui Y. Heparansulphate and heparin as a potentiator or a suppressor of growt of normal and trasformed vascular endothelial cells Exp Cell Res 1987;172:92-100
19. Bollu J, Kumar S. Effects of heparin, eparan sulphate and dermatan sulphate on fibrinolysis, by tissue plasminogen activator FASEB J 1988,2(A344):276-81.
20. Blardi P, Messa GL, Bononi LJ, Auteri A, Di Pern T. Pharmacoclynamic of heparan sulphate given orally in patients with chronic venous insufficiency Ann Meet of the Phlebol Soc, Las Vegas 1989.
21. Allegra G Endotelio come organo. l'eparansolfato estrattivo. In: Endotelio come organo. Patologia vascolare ed eparan solfato. Milano PRAGMA Ed. 1991;6:131-64.
22. Fiore G, Baraldi A, Gambarotta C et al Inhibition of plasminogen activator inhibitor (PAI-1) by sulodexide in post-thrombophlebitic patients. J Drug Devel 1991;3:173-8
23. Luttichau U, Palazzini E Pharmacological treatment of post-phlebitic syndromes with sulodexide. Med Praxis 1992;13:1-8.
24. Saviano M, Maleti O, Liguori L et al. Double-blind, double-dummy, randomised, multicentre clinical assessment of efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin 1993;13:96-108.
25. Von Kaulla KN, Schultz RL. Methods for the evaluation of human fibrinolysis. Am J Clin Pathol 1958; 29:104-12.
26. Chmielewska J, Wiman B Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. Clin Chem 1986;32:422-89.
27. Nilsson K, Rosen S, Friberger P. A new kit for the determination of tissue plasminogen and its inhibitor in blood. Fibrinolysis 1987;1:163-8.
28. Jacques LB. Heparins anionic polyelectrolyte drugs. Pharmacol Rev 1980;31:99-166.
29. Marcum JA, Rosenberg R. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984;23:1730-7.